Geode Capital Management
TARS icon

Geode Capital Management’s Tarsus Pharmaceuticals TARS Stock Holding History

Geode Capital Management’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$69.6M Sell
1,105,689
-15,402
-1% -$984K ﹤0.01% 1450
2026
Q1 		$78.7M Buy
1,121,091
+173,328
+18% +$12.1M ﹤0.01% 1238
2025
Q4 		$77.6M Buy
947,763
+3,267
+0.3% +$244K ﹤0.01% 1239
2025
Q3 		$56.1M Buy
944,496
+10,076
+1% +$496K ﹤0.01% 1401
2025
Q2 		$37.9M Buy
934,420
+68,986
+8% +$3.1M ﹤0.01% 1577
2025
Q1 		$44.5M Buy
865,434
+26,630
+3% +$1.32M ﹤0.01% 1437
2024
Q4 		$46.5M Buy
838,804
+3,014
+0.4% +$137K ﹤0.01% 1482
2024
Q3 		$27.5M Buy
835,790
+62,555
+8% +$1.76M ﹤0.01% 1809
2024
Q2 		$21M Buy
773,235
+143,543
+23% +$4.83M ﹤0.01% 1907
2024
Q1 		$22.9M Buy
629,692
+19,956
+3% +$587K ﹤0.01% 1848
2023
Q4 		$12.3M Buy
609,736
+83,476
+16% +$1.39M ﹤0.01% 2217
2023
Q3 		$9.35M Buy
526,260
+81,399
+18% +$1.44M ﹤0.01% 2310
2023
Q2 		$8.04M Buy
444,861
+95,712
+27% +$1.52M ﹤0.01% 2422
2023
Q1 		$4.39M Buy
349,149
+7,958
+2% +$116K ﹤0.01% 2690
2022
Q4 		$5M Buy
341,191
+11,710
+4% +$194K ﹤0.01% 2666
2022
Q3 		$5.64M Buy
329,481
+63,397
+24% +$1.01M ﹤0.01% 2605
2022
Q2 		$3.88M Buy
266,084
+135,326
+103% +$2.03M ﹤0.01% 2834
2022
Q1 		$2.2M Buy
130,758
+4,943
+4% +$91.7K ﹤0.01% 3215
2021
Q4 		$2.83M Buy
125,815
+2,117
+2% +$55K ﹤0.01% 3197
2021
Q3 		$2.67M Sell
123,698
-1,823
-1% -$45.1K ﹤0.01% 3233
2021
Q2 		$3.64M Buy
125,521
+23,712
+23% +$741K ﹤0.01% 3080
2021
Q1 		$3.28M Sell
101,809
-8,566
-8% -$317K ﹤0.01% 2998
2020
Q4 		$4.56M Buy
+110,375
New +$3.14M ﹤0.01% 2651

Other funds holding TARS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Geode Capital Management's TARS Position: Q2 2026 in Review

Geode Capital Management reduced its Tarsus Pharmaceuticals (TARS) stake by 1.4% in Q2 2026, selling an estimated $984K and leaving 1,105,689 shares worth $69.6M. The position accounts for ﹤0.01% of the portfolio, ranked #1450.

Geode Capital Management first reported a position in TARS in Q4 2020 and has held it in 23 quarters since. The position peaked at $78.7M in Q1 2026. 257 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

  • Geode Capital Management held 1,105,689 shares of Tarsus Pharmaceuticals worth $69.6M as of Q2 2026.
  • Geode Capital Management sold 15,402 Tarsus Pharmaceuticals shares in Q2 2026, an estimated $984K.
  • Tarsus Pharmaceuticals made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #1450 holding.
  • Geode Capital Management first reported a position in Tarsus Pharmaceuticals in Q4 2020 and has held it in 23 quarters since.
  • Geode Capital Management's Tarsus Pharmaceuticals position peaked at $78.7M in Q1 2026.
  • 257 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.